Diagnosis and Therapy of Visceral Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
This article gives an overview of current diagnostic and therapeutic strategies.PMID:37992729 | DOI:10.1055/a-2178-6670 (Source: Hamostaseologie)
Source: Hamostaseologie - November 22, 2023 Category: Hematology Authors: Katja S M ühlberg Source Type: research
Cancer-Associated Venous Thromboembolism-Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2023 Nov 22. doi: 10.1055/a-2178-6508. Online ahead of print.ABSTRACTPatients with cancer are prone to develop venous thromboembolism (VTE) with negative impact on quality of life, morbidity, and mortality. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE (CAT) basically comprises initial and maintenance treatment, for 3 to 6 months, secondary preventions, and treatment in special situations. Therapeutic anticoagulation is the treatment of choice in CAT. In addition to the efficacy and safety of low-molecular-weight heparin (LMWH) that had been recom...
Source: Hamostaseologie - November 22, 2023 Category: Hematology Authors: Hanno Riess Jan Beyer-Westendorf Uwe Pelzer Robert Klamroth Birgit Linnemann Source Type: research
Diagnosis and Therapy of Visceral Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
This article gives an overview of current diagnostic and therapeutic strategies.PMID:37992729 | DOI:10.1055/a-2178-6670 (Source: Hamostaseologie)
Source: Hamostaseologie - November 22, 2023 Category: Hematology Authors: Katja S M ühlberg Source Type: research
Cancer-Associated Venous Thromboembolism-Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2023 Nov 22. doi: 10.1055/a-2178-6508. Online ahead of print.ABSTRACTPatients with cancer are prone to develop venous thromboembolism (VTE) with negative impact on quality of life, morbidity, and mortality. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE (CAT) basically comprises initial and maintenance treatment, for 3 to 6 months, secondary preventions, and treatment in special situations. Therapeutic anticoagulation is the treatment of choice in CAT. In addition to the efficacy and safety of low-molecular-weight heparin (LMWH) that had been recom...
Source: Hamostaseologie - November 22, 2023 Category: Hematology Authors: Hanno Riess Jan Beyer-Westendorf Uwe Pelzer Robert Klamroth Birgit Linnemann Source Type: research
Diagnosis and Therapy of Visceral Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
This article gives an overview of current diagnostic and therapeutic strategies.PMID:37992729 | DOI:10.1055/a-2178-6670 (Source: Hamostaseologie)
Source: Hamostaseologie - November 22, 2023 Category: Hematology Authors: Katja S M ühlberg Source Type: research
Cancer-Associated Venous Thromboembolism-Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2023 Nov 22. doi: 10.1055/a-2178-6508. Online ahead of print.ABSTRACTPatients with cancer are prone to develop venous thromboembolism (VTE) with negative impact on quality of life, morbidity, and mortality. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE (CAT) basically comprises initial and maintenance treatment, for 3 to 6 months, secondary preventions, and treatment in special situations. Therapeutic anticoagulation is the treatment of choice in CAT. In addition to the efficacy and safety of low-molecular-weight heparin (LMWH) that had been recom...
Source: Hamostaseologie - November 22, 2023 Category: Hematology Authors: Hanno Riess Jan Beyer-Westendorf Uwe Pelzer Robert Klamroth Birgit Linnemann Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
THROMKIDplus Patient Registry and Biomaterial Banking for Children with Inherited Platelet Disorders
Hamostaseologie. 2023 Nov 2. doi: 10.1055/a-2117-4639. Online ahead of print.ABSTRACTInherited platelet disorders (IPDs) represent a heterogeneous group of disorders that include both quantitative (thrombocytopenia or thrombocytosis) and qualitative (thrombocytopathy) defects. To gain better knowledge about the prevalence, pathogenesis, and clinical consequences of specific diseases, to improve diagnosis and treatment of patients with IPD, and to support translational research on a genetic, molecular, and physiological basis, the THROMKIDplus study group currently comprising 24 sites in Germany, Austria, and Switzerland de...
Source: Hamostaseologie - November 2, 2023 Category: Hematology Authors: Matthias Ballmaier Manuela Germeshausen Harald Schulze Oliver Andres THROMKIDplus Study Group Source Type: research
